Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764578 | 1.00 | HDAC6 (0.58) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL27241012 | 1.00 | HDAC6 (0.58) | HDAC6LMNAALDH1A1TP53MAPT | |
| Hydrochloric Acid SCHEMBL31273762 | 0.99 | HDAC6 (0.57) | HDAC6LMNAALDH1A1TP53MAPT | |
| Hydrochloric Acid SCHEMBL27241013 | 0.99 | HDAC6 (0.57) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7208094 | 0.92 | HDAC6 (0.55) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7208090 | 0.92 | HDAC6 (0.55) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7864610 | 0.91 | HDAC6 (0.48) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7864607 | 0.91 | HDAC6 (0.48) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7214248 | 0.91 | HDAC6 (0.68) | HDAC6LMNAALDH1A1TP53MAPT | |
| SCHEMBL7215029 | 0.91 | HDAC6 (0.60) | HDAC6LMNAALDH1A1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | claimed |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170002035-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (GB) | 2017-01-05 | — | — | US | disclosed |
| US-20160030460-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9163052-B2 | Crystalline forms of an antiviral benzimidazole compound | GLAXOSMITHKLINE LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130261294-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLAXOSMITHKLINE LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20110118203-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLAXOSMITHKLINE LLC | 2011-05-19 | — | — | US | disclosed |
| US-20100179101-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | GLOVER BOBBY NEAL | 2010-07-15 | — | — | US | disclosed |
| US-7714123-B2 | Crystalline forms of an antiviral benzimidazole compound | GLAXOSMITHKLINE LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20080103186-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXOSMITHKLINE LLC | 2008-05-01 | — | — | US | disclosed |
| EP-1071693-B1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | GLAXO GROUP LTD (GB) | 2004-03-10 | — | — | EP | disclosed |
| US-6617315-B1 | Sugar-substituted benzimidazole derivatives are used for the treatment or prophylaxis of restenosis, particularly following angioplasty | CHAMBERLAIN STANLEY DAWES (US) | 2003-09-09 | — | — | US | disclosed |
| US-6482939-B1 | Form vi 5,6-dichloro-2-(isopropylamino)-1-(β-l-ribofuranosyl)-1h-bezimimidazole | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-6469160-B1 | 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H -BENZIMIDAZOLE (AKA 1263W94) OF GIVEN X-RAY DIFFRACTION PATTERN | SMITHKLINE BEECHAM CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | disclosed |
| US-6077832-A | FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION | GLAXO WELLCOME INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179101-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 96/4885LMNA 2913/4885ALDH1A1 2300/4885 |
| US-20110118203-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885LMNA 2936/4885ALDH1A1 2608/4885 |
| US-20080103186-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 96/4885LMNA 2913/4885ALDH1A1 2300/4885 |
| US-20130261294-A1 | Novel Crystalline Forms Of An Antiviral Benzimidazole Compound | EIF2AK2, ZC3HAV1, MAVS | HDAC6 96/4885LMNA 2913/4885ALDH1A1 2300/4885 |
| US-20180044366-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885LMNA 2936/4885ALDH1A1 2608/4885 |
| US-20170002035-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885LMNA 2936/4885ALDH1A1 2608/4885 |
| US-20160030460-A1 | NOVEL CRYSTALLINE FORMS OF AN ANTIVIRAL BENZIMIDAZOLE COMPOUND | EIF2AK2, ZC3HAV1, MAVS | HDAC6 105/4885LMNA 2936/4885ALDH1A1 2608/4885 |
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | HDAC6 78/4885LMNA 3592/4885ALDH1A1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.